Tag : CBD product

Politics

DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

Editor
The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The CBD product Epidiolex is derived from the cannabis...
Cannabis News Global Health Hemp News Market Watch

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)

Editor
On February 27, 2018, GW Pharmaceuticals, PLC (Nasdaq:GWPH) (“GW) announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW has started a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of...